Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03118570 · ClinicalTrials.gov registry record · Phase 2
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
A Phase 2 study, sponsored by Ultragenyx Pharmaceutical.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT03118570 is a Phase 2 study that has completed, run by Ultragenyx Pharmaceutical. The registered enrollment target is 112 participants.
The verdict
NCT03118570, a Phase 2 study, has completed, sponsored by Ultragenyx Pharmaceutical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
The purpose of this study is to select a suitable dose of BPS804 by measuring the strength/quality of bone using a special type of CT scanner. Participants will be treated for 12 months and followed up for a further 12 months.
Interventions
- DIETARY_SUPPLEMENT Vitamin D
- DIETARY_SUPPLEMENT Calcium
- DRUG setrusumab
- DRUG zoledronic acid (optional)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2017-09-11 |
| Est. Completion | 2020-11-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03118570
The ClinicalTrials.gov registry entry for NCT03118570 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vitamin D is the first listed.
NCT03118570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03118570 about?
NCT03118570 is a clinical study titled "A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804". The purpose of this study is to select a suitable dose of BPS804 by measuring the strength/quality of bone using a special type of CT scanner. Participants will be treated for 12 months and followed up for a further 12 months.
What is the current status of trial NCT03118570?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2017-09-11. Estimated completion is 2020-11-12.
What interventions are being tested in trial NCT03118570?
The interventions under investigation include: Vitamin D (DIETARY_SUPPLEMENT), Calcium (DIETARY_SUPPLEMENT), setrusumab (DRUG), zoledronic acid (optional) (DRUG).
Who is sponsoring clinical trial NCT03118570?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.